In vivo characterization of the opioid antagonist nalmefene in mice

Life Sciences

Volumn 86, Issue 15-16, 2010, Pages 624-630

  Osborn, Melissa D ^a   Lowery, John J ^b   Skorput, Alex G J ^b   Giuvelis, Denise ^b   Bilsky, Edward J ^b  

^a UNIVERSITY OF NEW ENGLAND   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

Author keywords

Antinociception; Mu opioid receptor; Opioid antagonist; Pain

Indexed keywords

MORPHINE; NALMEFENE; NALOXONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; IN VIVO STUDY; LOCOMOTION; MALE; MOUSE; NONHUMAN; TAIL FLICK TEST; WITHDRAWAL SYNDROME;

ANALGESICS, OPIOID; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INHIBITORY CONCENTRATION 50; MALE; MICE; MICE, INBRED ICR; MORPHINE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN; SUBSTANCE WITHDRAWAL SYNDROME; TIME FACTORS;

MUS;

EID: 77950689016     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.02.013     Document Type: Article

References (21)

1. 2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. Journal of Pharmacology and Experimental Therapeutics 1996, 277(1):484-490.
2. Blasig J., Herz A., Reinhold K., Zieglgansberger S. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 1973, 33(1):19-38.
3. Bokoch M.P., Zou Y., Rasmussen S.G., Liu C.W., Nygaard R., Rosenbaum D.M., Fung J.J., Choi H.J., Thian F.S., Kobilka T.S., Puglisi J.D., Weis W.I., Pardo L., Prosser R.S., Mueller L., Kobilka B.K. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010, 463(7277):108-112.
4. Divin M.F., Holden Ko M.C., Traynor J.R. Comparison of the opioid receptor antagonist properties of naltrexone and 6ß-naltrexol in morphine-naïve and morphine-dependent mice. European Journal of Pharmacology 2008, 583(1):48-55.
5. Fujimoto J.M., Roerig S., Wang R.I., Chatterjie N., Inturrisi C.E. Narcotic antagonist activity of several metabolites of naloxone and naltrexone tested in morphine dependent mice. Proceedings for the Society of Experimental Biology and Medicine 1975, 148(2):443-448.
6. Glass P.S., Jhaveri R.M., Smith L.R. Comparison of potency and duration of action of nalmefene and naloxone. Anesthesia and Analgesia 1994, 78(3):536-541.
7. Grant J.E., Potenza M.N., Hollander E., Cunningham-Williams R., Nurminen T., Smits G., Kallio A. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. American Journal of Psychiatry 2006, 163(2):303-312.
8. Jannsen P.A.J., Niemegeers C.J.E., Dorg J.G.H. The inhibitory effects of fentanyl and other morphine-like analgesics on the warm water-induced tail withdrawal reflex in rats. ArzneimForsch 1963, 13:502-505.
9. Kaplan J.L., Marx J.A., Calabro J.J., Gin-Shaw S.L., Spiller J.D., Spivey W.L., Gaddis G.M., Zhao N., Harchelroad F.P. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Annals of Emergency Medicine 1999, 34(1):42-50.
10. Karhuvaara S., Simojoki K., Virta A., Rosberg M., Löyttyniemi E., Nurminen T., Kallio A., Mäkelä R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study. Alcoholism: Clinical and Experimental Research 2007, 31(7):1179-1187.
11. Kest B., Palmese C.A., Hopkins E., Adler M., Juni A., Mogil J.S. Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 2002, 115(2):463-469.
12. Kjellberg F., Tramèr M.R. Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials. European Journal of Anaesthesiology 2001, 18(6):346-357.
13. Klein G., Juni A., Arout C.A., Waxman A.R., Inturrisi C.E., Kest B. Acute and chronic heroin dependence in mice: contribution of opioid and excitatory amino acid receptors. European Journal of Pharmacology 2008, 586(1-3):179-188.
14. Mason B.J., Salvato F.R., Williams L.D., Ritvo E.C., Cutler R.B. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Archives of General Psychiatry 1999, 56(8):719-724.
15. Pellegrini J.E., Bailey S.L., Graves J., Paice J.A., Shott S., Faut-Callahan M. The impact of nalmefene on side effects due to intrathecal morphine at cesarean section. AANA Journal 2001, 69(3):199-205.
16. Raehal K.M., Lowery J.J., Bhamidipati C.M., Paolino R.M., Blair J.R., Wang D., Sadée W., Bilsky E.J. In vivo characterization of 6β-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. Journal of Pharmacology and Experimental Therapeutics 2005, 313(3):1150-1162.
17. Sadée W., Wang D., Bilsky E.J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sciences 2005, 76(13):1427-1437.
18. Sirohi S., Dighe S.V., Madia P.A., Yoburn B.C. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity. Journal of Pharmacology and Experimental Therapeutics 2009, 330(3):513-519.
19. Wang D.S., Sternbach G., Varon J. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine. Journal of Emergency Medicine 1998, 16(3):471-475.
20. Wang D., Raehal K.M., Bilsky E.J., Sadée W. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. Journal of Neurochemistry 2001, 77(6):1590-1600.
21. Wang D., Raehal K.M., Lin E.T., Lowery J.J., Kieffer B.L., Bilsky E.J., Sadée W. Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. Journal of Pharmacology and Experimental Therapeutics 2004, 308(2):512-520.